ZUG, Switzerland--(BUSINESS WIRE)--PSI CRO, global full-service contract research organization, announced today that PSI’s scientific expertise is represented with an abstract publication at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, which begins this week in Chicago.
The published abstract, Co-Morbidity in Clinical Trial Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), is authored by PSI’s Medical Affairs Department and is based on more than a decade of experience that PSI has gathered running global studies in advanced or metastatic non-small cell lung cancer.
PSI will be fully represented at ASCO 2016 at Booth #12081 beginning Saturday June 4th through Monday June 6th at the McCormick Place Convention. PSI is actively working in all major indications in Oncology.
About PSI CRO:
PSI is a privately-owned, full-service contract research organization (CRO), operating globally. PSI’s reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com